Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

114.03
-1.2050-1.05%
Post-market: 114.950.9235+0.81%19:30 EDT
Volume:878.99K
Turnover:100.01M
Market Cap:12.33B
PE:251.35
High:115.98
Open:114.29
Low:111.94
Close:115.23
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.91
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.46
PE(LYR):139.05

Loading ...

Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million

Reuters
·
Aug 13

Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks

Simply Wall St.
·
Aug 06

Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40

Reuters
·
Aug 06

We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings

Simply Wall St.
·
Aug 05

Why Corcept Therapeutics (CORT) Is Up 19.8% After Boosting 2026 Revenue Guidance And Earnings

Simply Wall St.
·
Aug 04

Corcept CFO Atabak Mokari Sells 79,000 Shares Worth $8.95 Million

Reuters
·
Aug 04

3 High Growth Stocks Investors May Be Missing Right Now

Simply Wall St.
·
Aug 03

Coursera Stock And 2 More Growth Picks Backed By Healthy Balance Sheets

Simply Wall St.
·
Aug 02

OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

TIPRANKS
·
Aug 01

LIVE Markets-us Earnings Forecast Jumps Further After Key Reports This Week

Reuters
·
Aug 01

Movement Alert|Corcept Therapeutics Falls 5.04% in Regular Trading, Profit-Taking After Prior Session Earnings-Driven Surge Amid Broad Pharma Weakness

Market Focus
·
Jul 31

Workday Stock And 2 Software Picks Backed By Insider Confidence

Simply Wall St.
·
Jul 31

Corcept Therapeutics Price Target Raised to $165.00/Share from $88.00 by Piper Sandler

Dow Jones
·
Jul 31

Corcept Therapeutics Shares Rally After Revenue Guidance Raised

Dow Jones
·
Jul 30

Movement Alert|Corcept Therapeutics Rises 15.98% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance

Market Focus
·
Jul 30

Disc Medicine Posts Smaller-than-expected Q2 Net Loss

Reuters
·
Jul 30

Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth

Reuters
·
Jul 30

Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright

TIPRANKS
·
Jul 30

Premarket Movers | CORT Surges 26% as Q2 Earnings Easily Beat Expectations and Full-Year Guidance Is Raised

Market Focus
·
Jul 30

Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $161 from $150

THOMSON REUTERS
·
Jul 30